Caribou Biosciences (CRBU) 7th Annual Evercore ISI HealthCONx Conference summary

Company overview and technology

• Focused on developing off-the-shelf CAR-T cell therapies using proprietary chRDNA CRISPR genome editing technology for hematologic malignancies and autoimmune diseases.

• Three ongoing phase I clinical studies: non-Hodgkin lymphoma (CB-010), multiple myeloma (CB-011), and AML (CB-012), with three data readouts expected in the first half of next year.

• Committed to advancing to a pivotal trial in second-line large B-cell lymphoma by end of next year, targeting patients with prior CD19 therapy.

Editing strategies and platform differentiation

• Employs disease-specific editing: PD-1 knockout for lymphoma, immune cloaking for myeloma, and a combination for AML, leveraging chRDNA for high-efficiency, multi-edit engineering.

• HLA matching shown to improve efficacy and persistence in lymphoma, with a four-plus match correlating with outcomes rivaling autologous CAR-T therapies.

• Best-match HLA strategy being built for myeloma and AML as data matures.

Clinical data and trial progress

• In the ANTLER trial for CB-010, a 44% six-month CR rate was achieved in third-line patients, outperforming the 35% benchmark for autologous CAR-T.

• Second-line patients are sicker, but HLA-matched subsets show efficacy comparable to autologous therapies.

• Confirmatory 20-patient cohort in second-line lymphoma to report in the first half of next year, with plans for a pivotal phase III trial by year-end if results hold.